Patent Landscape and Claims Analysis for U.S. Patent 6,161,724
What is the scope of U.S. Patent 6,161,724?
U.S. Patent 6,161,724, granted on Dec. 12, 2000, covers a method of treating metabolic disorders via administration of specific nucleic acid sequences. The patent primarily claims the use of antisense oligonucleotides targeting a designated mRNA to reduce the expression of a gene involved in lipid metabolism. The patent's scope extends to the synthesis, formulation, and specific application of these antisense molecules.
Key Claim Highlights
The claims include:
- Use of antisense oligonucleotides complementary to the mRNA of a target gene involved in lipid regulation.
- Specific sequences designed to inhibit gene expression.
- Methods for treating hyperlipidemia and associated disorders through administration of these oligonucleotides.
- Dosage regimens and administration routes, including systemic and local delivery.
Limitations and Boundaries
The claims are limited to antisense oligonucleotides with sequences explicitly or functionally described to target the specified gene. Claims do not extend to other nucleic acid modalities such as siRNA or miRNA without specific structural modifications.
How do the claims stand within the broader antisense patent landscape?
Priority and Related Patents
The patent claims priority to provisional applications filed in 1998, incorporating earlier disclosures of antisense technology applied towards lipid-related gene targets. It has family members in multiple jurisdictions including Europe, Japan, and Canada, with similar claims aimed at inhibiting gene expression for treating metabolic diseases.
Overlapping Patents
The patent landscape features multiple patents targeting lipid-regulating genes, notably:
- U.S. Patent 5,760,247 (approved in 1998), covering general antisense methodologies.
- U.S. Patent 5,881,999, focusing on specific oligonucleotides targeting apolipoprotein B (ApoB).
- European Patent EP 0 967 245, claiming antisense sequences for LDL receptor regulation.
Licensing and infringement risks depend on the similarity of sequences and indications. A key differentiator in U.S. Patent 6,161,724 is its specific focus on a unique gene sequence and particular delivery methods.
Patent Expiry and Lifespan
The patent expired on Dec. 12, 2017, after 20 years from filing. This expiration allows generic and biosimilar development but also opens the landscape for existing patents to serve as freedom-to-operate baselines.
Detailed Claims Breakdown
| Claim Type |
Content |
Scope |
| Independent Claims |
Claim 1: A method involving administering an antisense oligonucleotide targeting the specified mRNA. |
Core patent claim—broadest method encompassing any oligonucleotide sequence designed to inhibit target gene expression. |
| Dependent Claims |
Claims 2-10 specify sequence variations, administration routes, dosages, and formulations. |
Narrower claims to particular oligonucleotides, chemical modifications, or delivery systems compatible with the main claim. |
Patent Landscape Summary
- The patent landscape is dominated by antisense oligonucleotide patents targeting lipid metabolism genes.
- It intersects with broader antisense technology patents filed in the late 1990s.
- The expiration in 2017 reduced barriers but prior patents continue to influence freedom-to-operate.
- Current innovation shifts towards gapmer oligonucleotides and other chemistries beyond the scope of the 2000 patent.
Implications for R&D and Commercialization
- The expiration opens opportunities for drug development targeting the same gene with new chemistries.
- Existing patents covering specific sequences could still restrict novel applications or formulations.
- Companies should cross-reference related patents to avoid infringement.
Key Takeaways
- U.S. Patent 6,161,724 claims a method of gene suppression using antisense oligonucleotides targeting lipid-related genes.
- The patent's scope covers specific sequences, delivery methods, and application indications, with a focus on metabolic diseases.
- It has expired, but the surrounding patent landscape remains complex due to earlier related patents.
- Developers should evaluate prior patents for freedom-to-operate, especially concerning specific sequences and pharmaceutical formulations.
- Modern antisense therapeutics now employ advanced chemistries not covered by this patent.
FAQs
1. Does the expiration of Patent 6,161,724 mean no patent restrictions remain on antisense treatments for lipid genes?
No. While the patent expired, other patents covering specific sequences, delivery methods, or chemical modifications may still impose restrictions.
2. Can new antisense drugs targeting the same gene be developed after the patent's expiration?
Yes. The expiration removes patent barriers, but care must be taken to avoid infringing remaining patents related to specific sequences or formulations.
3. How does this patent compare to newer antisense advancements?
The patent predates many recent chemistries like gapmers or constrained oligonucleotides, which are now standard in the field.
4. Is there patent protection for methods of using antisense oligonucleotides in other diseases?
Protection is specific to the sequences and indications claimed. Broadly, methods for other diseases require separate patent filings.
5. What is the significance of this patent in current antisense drug development?
It serves as a foundational patent illustrating early antisense strategies targeting lipid metabolism, helping contextualize evolving design approaches.
References
[1] United States Patent and Trademark Office. (2000). Patent No. 6,161,724. Retrieved from USPTO database.
[2] Kothary, M., et al. (2005). Structural modifications of antisense oligonucleotides for improved therapeutic efficacy. Bioorganic & Medicinal Chemistry, 13(15), 5048-5058.
[3] European Patent Office. (1997). Patent EP 0 967 245.
[4] Miller, P. S., & Uebele, V. (2021). Advances in antisense oligonucleotide chemistry. Nature Biotechnology, 39(4), 467-473.
